Travere Therapeutics (TVTX)
Develops and sells rare kidney-disease medicines led by FILSPARI.
$60.28
After hours0.00 (0.00%)
At close$60.28(−4.10%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 112.57% | 106.11M shares | |
|---|---|---|---|
| 332 holders · as of Jun 30, 2026 | |||
| Insiders | 1.55% | 1.46M shares | |
| 16 holders · as of Sep 17, 2026 | |||
| Strategic holders | 11.25% | 10.60M shares | |
| 1 holder · as of Nov 14, 2025 | |||
| Adds to | 125.37% | ||
94.26M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 125.37%; nothing is left for Other.
13F, as of Jun 30, 2026
332 holders · 106.11M shares · 89 new positions · 211 increased · 87 reduced · 32 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Jupiter Topco LLC | 11.32M | 12.01% | +11.32Mnew | Aug 14, 2026 |
| BlackRock, Inc. | 8.02M | 8.51% | +228.6K | Aug 7, 2026 |
| FMR LLC | 7.10M | 7.53% | −3.87M | Aug 13, 2026 |
| Bank of America Corp /DE/ | 4.57M | 4.85% | +3.22M | Aug 14, 2026 |
| State Street Corp | 4.26M | 4.52% | −703.8K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 4.11M | 4.36% | +62.9K | Aug 13, 2026 |
| Perceptive Advisors LLC | 3.75M | 3.98% | −390.0K | Aug 14, 2026 |
| Macquarie Management Holdings, Inc. | 2.81M | 2.98% | −458.0K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 11.90% | 10.60M | 13G | Nov 14, 2025 |
| FMR LLC | 11.70% | 10.57M | 13G | Jan 8, 2026 |
| Armistice Capital, LLC | 9.96% | 8.88M | 13G | Aug 15, 2025 |
| BlackRock, Inc. | 7.50% | 6.69M | 13G | Apr 17, 2025 |
| Bank of America Corp /DE/ | 5.80% | 5.44M | 13G | Aug 12, 2026 |
| Woodline Partners LP | 5.70% | 4.34M | 13G | Nov 14, 2024 |
| Vanguard Capital Management | 5.09% | 4.70M | 13G | Apr 30, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 15, 2026 | Elizabeth E. Reedofficer: Chief Legal Officer and GC | Sale · 4 lots | 37,500 | $62.34 | 105,389 |
| Sep 15, 2026 | Jula Inrigofficer: EVP, Head of R&D & CMO | Sale · 4 lots | 44,674 | $62.34 | 100,491 |
| Sep 17, 2026 | Peter Heermaofficer: EVP, CHIEF COMMERCIAL OFFICER | Sale | 8,282 | $65.07 | 117,066 |
| Sep 16, 2026 | Peter Heermaofficer: EVP, CHIEF COMMERCIAL OFFICER | Sale · 2 lots | 172,717 | $63.43 | 117,066 |
| Sep 15, 2026 | Peter Heermaofficer: EVP, CHIEF COMMERCIAL OFFICER | Sale · 4 lots | 102,190 | $62.26 | 117,066 |
| Sep 16, 2026 | William E. Roteofficer: Chief Research Officer | Sale · 2 lots | 112,850 | $63.33 | 98,197 |
| Sep 15, 2026 | William E. Roteofficer: Chief Research Officer | Sale · 4 lots | 96,198 | $62.25 | 98,197 |
| Sep 15, 2026 | Sandra Calvinofficer: SVP, CHIEF ACCOUNTING OFFICER | Sale · 3 lots | 5,375 | $62.33 | 42,353 |
| Sep 15, 2026 | Christopher R. Clineofficer: CHIEF FINANCIAL OFFICER | Sale · 4 lots | 50,508 | $62.34 | 87,508 |
| Sep 17, 2026 | Eric M. Dubedirector, officer: CHIEF EXECUTIVE OFFICER | Sale · 2 lots | 108,493 | $64.61 | 432,886 |
House and Senate disclosures
Not reported.